641 related articles for article (PubMed ID: 37240238)
21. The use of personalized biomarkers and liquid biopsies to monitor treatment response and disease recurrence in locally advanced rectal cancer after neoadjuvant chemoradiation.
Carpinetti P; Donnard E; Bettoni F; Asprino P; Koyama F; Rozanski A; Sabbaga J; Habr-Gama A; Parmigiani RB; Galante PA; Perez RO; Camargo AA
Oncotarget; 2015 Nov; 6(35):38360-71. PubMed ID: 26451609
[TBL] [Abstract][Full Text] [Related]
22. [Liquid biopsy in colorectal cancer : An overview of ctDNA analysis in tumour diagnostics].
Haupts A; Roth W; Hartmann N
Pathologe; 2019 Dec; 40(Suppl 3):244-251. PubMed ID: 31797045
[TBL] [Abstract][Full Text] [Related]
23. The potential of liquid biopsy in the management of cancer patients.
Markou A; Tzanikou E; Lianidou E
Semin Cancer Biol; 2022 Sep; 84():69-79. PubMed ID: 35331850
[TBL] [Abstract][Full Text] [Related]
24. Circulating Tumor DNA: A Step into the Future of Cancer Management.
Fernandes Marques J; Pereira Reis J; Fernandes G; Hespanhol V; Machado JC; Costa JL
Acta Cytol; 2019; 63(6):456-465. PubMed ID: 30852572
[TBL] [Abstract][Full Text] [Related]
25. Development and Application of Liquid Biopsies in Metastatic Prostate Cancer.
Morrison GJ; Goldkorn A
Curr Oncol Rep; 2018 Mar; 20(4):35. PubMed ID: 29572775
[TBL] [Abstract][Full Text] [Related]
26. Liquid biopsy tracking of lung tumor evolutions over time.
Russo A; De Miguel Perez D; Gunasekaran M; Scilla K; Lapidus R; Cooper B; Mehra R; Adamo V; Malapelle U; Rolfo C
Expert Rev Mol Diagn; 2019 Dec; 19(12):1099-1108. PubMed ID: 31608732
[No Abstract] [Full Text] [Related]
27. The Present and Future of Liquid Biopsies in Non-Small Cell Lung Cancer: Combining Four Biosources for Diagnosis, Prognosis, Prediction, and Disease Monitoring.
Bracht JWP; Mayo-de-Las-Casas C; Berenguer J; Karachaliou N; Rosell R
Curr Oncol Rep; 2018 Jul; 20(9):70. PubMed ID: 30030656
[TBL] [Abstract][Full Text] [Related]
28. Liquid Biopsy as a Tool for the Diagnosis, Treatment, and Monitoring of Breast Cancer.
Freitas AJA; Causin RL; Varuzza MB; Calfa S; Hidalgo Filho CMT; Komoto TT; Souza CP; Marques MMC
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077348
[TBL] [Abstract][Full Text] [Related]
29. Circulating biomarkers for early detection and clinical management of colorectal cancer.
Marcuello M; Vymetalkova V; Neves RPL; Duran-Sanchon S; Vedeld HM; Tham E; van Dalum G; Flügen G; Garcia-Barberan V; Fijneman RJ; Castells A; Vodicka P; Lind GE; Stoecklein NH; Heitzer E; Gironella M
Mol Aspects Med; 2019 Oct; 69():107-122. PubMed ID: 31189073
[TBL] [Abstract][Full Text] [Related]
30. Liquid Biopsy in Solid Malignancy.
Scarlotta M; Simsek C; Kim AK
Genet Test Mol Biomarkers; 2019 Apr; 23(4):284-296. PubMed ID: 30916594
[TBL] [Abstract][Full Text] [Related]
31. Liquid Biopsies for Neuroendocrine Tumors: Circulating Tumor Cells, DNA, and MicroRNAs.
Rizzo FM; Meyer T
Endocrinol Metab Clin North Am; 2018 Sep; 47(3):471-483. PubMed ID: 30098711
[TBL] [Abstract][Full Text] [Related]
32. A headlight on liquid biopsies: a challenging tool for breast cancer management.
Massihnia D; Perez A; Bazan V; Bronte G; Castiglia M; Fanale D; Barraco N; Cangemi A; Di Piazza F; Calò V; Rizzo S; Cicero G; Pantuso G; Russo A
Tumour Biol; 2016 Apr; 37(4):4263-73. PubMed ID: 26790442
[TBL] [Abstract][Full Text] [Related]
33. Liquid Biopsy beyond Circulating Tumor Cells and Cell-Free DNA.
Junqueira-Neto S; Batista IA; Costa JL; Melo SA
Acta Cytol; 2019; 63(6):479-488. PubMed ID: 30783027
[TBL] [Abstract][Full Text] [Related]
34. Cell-Free DNA in the Liquid Biopsy Context: Role and Differences Between ctDNA and CTC Marker in Cancer Management.
Fici P
Methods Mol Biol; 2019; 1909():47-73. PubMed ID: 30580422
[TBL] [Abstract][Full Text] [Related]
35. [Innovations in personalized medicine : Molecular characterization of liquid biopsy-fake or fact?].
Theil G; Fornara P
Urologe A; 2018 Sep; 57(9):1069-1074. PubMed ID: 29971453
[TBL] [Abstract][Full Text] [Related]
36. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R
Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770
[TBL] [Abstract][Full Text] [Related]
37. Tumor-Educated Platelet RNA and Circulating Free RNA: Emerging Liquid Biopsy Markers for Different Tumor Types.
Hu H; Song H; Han B; Zhao H; He J
Front Biosci (Landmark Ed); 2024 Feb; 29(2):80. PubMed ID: 38420812
[TBL] [Abstract][Full Text] [Related]
38. Liquid biopsy = Individualized cancer management: Diagnosis, monitoring treatment and checking recurrence and metastasis.
Mali SB; Dahivelkar S
Oral Oncol; 2021 Dec; 123():105588. PubMed ID: 34744021
[TBL] [Abstract][Full Text] [Related]
39. Liquid biopsy: Circulating exosomal long noncoding RNAs in cancer.
Jiang N; Pan J; Fang S; Zhou C; Han Y; Chen J; Meng X; Jin X; Gong Z
Clin Chim Acta; 2019 Aug; 495():331-337. PubMed ID: 31054913
[TBL] [Abstract][Full Text] [Related]
40. Applications of Circulating Tumor Cells and Circulating Tumor DNA in Precision Oncology for Breast Cancers.
Addanki S; Meas S; Sarli VN; Singh B; Lucci A
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
